Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. by Lunnon, Katie et al.
Journal of Alzheimer’s Disease 30 (2012) 685–710
DOI 10.3233/JAD-2012-111592
IOS Press
685
Mitochondrial Dysfunction and Immune
Activation are Detectable in Early
Alzheimer’s Disease Blood
Katie Lunnona,b,1, Zina Ibrahima,b,1, Petroula Proitsia,b, Anbarasu Lourdusamya,b,
Stephen Newhousea,b, Martina Sattleckera,b, Simon Furneya,b,3, Muzamil Saleema,b, Hilkka Soininenc,
Iwona Kłoszewskad, Patrizia Mecoccie, Magda Tsolakif , Bruno Vellasg, Giovanni Coppolah,
Daniel Geschwindh, Andrew Simmonsa,b, Simon Lovestonea,b, Richard Dobsona,b,2,
Angela Hodgesa,b,2,∗ and on Behalf of the AddNeuroMed Consortium
aInstitute of Psychiatry, King’s Health Partners Centre for Neurodegeneration Research, King’s College London,
London, UK
bNIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and
Institute of Psychiatry, King’s College London, London, UK
cDepartment of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
dMedical University of Lodz, Lodz, Poland
eInstitute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy
f3rd Department of Neurology, “G. Papanicolaou” Hospital, Aristotle University of Thessaloniki,
Thessaloniki, Greece
gINSERM U 558, University of Toulouse, Toulouse, France
hDepartment of Neurology, Programme inNeurogenetics, DavidGeffen School ofMedicine, University of California
at Los Angeles, CA, USA
Accepted 25 February 2012
Abstract. Alzheimer’s disease (AD), like other dementias, is characterized by progressive neuronal loss and neuroinflammation
in the brain. The peripheral leukocyte response occurring alongside these brain changes has not been extensively studied, but
might inform therapeutic approaches and provide relevant disease biomarkers. Using microarrays, we assessed blood gene
expression alterations occurring in people with AD and those with mild cognitive changes at increased risk of developing AD. Of
the 2,908 differentially expressed probes identified between the three groups (p < 0.01), a quarter were altered in blood from mild
cognitive impairment (MCI) and AD subjects, relative to controls, suggesting a peripheral response to pathology may occur very
early. There was strong evidence for mitochondrial dysfunction with decreased expression of many of the respiratory complex
I-V genes and subunits of the core mitochondrial ribosome complex. This mirrors changes previously observed in AD brain.
A number of genes encoding cell adhesion molecules were increased, along with other immune-related genes. These changes
are consistent with leukocyte activation and their increased the transition from circulation into the brain. In addition to expression
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changes, we also found increased numbers of basophils in people with MCI and AD, and increased monocytes in people with
an AD diagnosis. Taken together this study provides both an insight into the functional response of circulating leukocytes
during neurodegeneration and also identifies potential targets such as the respiratory chain for designing and monitoring future
therapeutic interventions using blood.
Keywords: Alzheimer’s disease, blood, gene expression pattern analysis, inflammation, late onset, mild cognitive impairment,
mitochondria
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form
of dementia. It is characterized by slow progressive
short term memory loss and the emergence of behav-
ioral symptoms such as psychosis, agitation, apathy,
and depression. Patients gradually lose their ability
to maintain personal care and death usually occurs
10–15 years following diagnosis. A combination of
an increasingly aging population and a current lack
of disease-modifying treatments will lead to an over-
whelmingly large number of people living with AD
in the coming years with far reaching social and eco-
nomic consequences [1]. Thus efforts to diagnose and
treat disease early, before considerable damage has
occurred, are a very high priority.
Probable AD is clinically diagnosed when robust
symptoms emerge such as problems with memory,
language, perceptual skills, attention, constructive
abilities, orientation, problem solving, and functional
abilities [2]. At present, diagnosis is only confirmed by
postmortem histopathological assessment. Against this
gold standard, clinical diagnostic accuracy can vary
from fair to excellent (65–96%) [3–6], highlighting the
reality of a disease which is clinically heterogeneous
and similar to other disorders. Accurate in-life diag-
nosis requires a high threshold of disease. Subclinical
disease has likely been present for decades before a
formal AD diagnosis is made [7, 8]. The emergence of
mild clinical symptoms such as memory complaints in
individuals with intact cognition and normal daily liv-
ing, which define Petersen’s criteria of mild cognitive
impairment (MCI) [9], may reflect the gradual and pro-
gressive appearance of plaques, neurofibrillary tangles,
cellular dysfunction, and loss of specific neuronal cells
which characterize AD. However, these symptoms can
sometimes represent another neurological disease or be
due to normal aging, as is the case for about 25% of
people with MCI [10].
Plaques and neurofibrillary tangles are pathologi-
cal hallmarks of AD and their generation is believed
to lead to the disruption of calcium homeostasis and
neuronal synapses, loss of connectivity, increased reac-
tive oxygen/nitrogen species, and altered plasticity in
vulnerable brain regions, culminating in progressive
neuronal cell death. Inappropriate neuroinflammation
[11–13] and mitochondrial dysfunction [14–17] are
consistent features of AD pathology in brain and are
important mechanisms through which toxicity may be
propagated.
Changes in AD are not just restricted to the brain. A
number of genes have altered abundance in AD blood,
some of which are sufficient to specifically and accu-
rately classify disease [18–20]. Preliminary evidence
suggests these changes may precede AD diagnosis
[21] but this has yet to be extensively investigated
in people with MCI. Mitochondria from peripheral
blood cells such as platelets and lymphocytes are
dysregulated [16, 22–24] and leukocytes from AD
patients are far more responsive to activation signals
[25]. Some AD blood cell vulnerabilities and disease-
associated changes may be linked to changes in levels
of amyloid- (A) peptides in plasma [26–29]. For
example, when ex vivo blood cells from AD patients
are treated with A1-42, there is a failure to upregu-
late MGAT3, a protein involved in A clearance [30].
MGAT3 may be useful as a prognostic biomarker of
disease deterioration [31]. Paralleling these alterations
in blood cell activity, changes in circulating cytokines,
chemokines, and other proteins, indicating activation
of the peripheral innate immune system occur in people
with MCI and AD [32–38].
A good strategy for further understanding disease
and treatment development might be to identify impor-
tant disease associated pathways in peripheral blood.
Blood is an easily accessible tissue which can be used
to assess changes occurring early in disease. Using
microarrays and a unique collection of blood samples,
with extensive demographic, clinical, and imaging data
available, we have identified differentially expressed
genes and altered biological processes in blood sam-
ples from people with MCI and AD. Changes in blood,
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which we believe reflect the disease processes occur-
ring in brain, could enable these cells to be used for
future design and monitoring of treatments against
disease-relevant biological processes.
METHODS AND MATERIALS
Subjects and samples
Blood samples for full blood cell count and mRNA
analyses were taken from subjects participating in
the AddNeuroMed study [39–41], involving six study
sites across Europe (London, Kuopio, Lodz, Perugia,
Thessaloniki, and Toulouse) or the London Dementia
Case Register (London). All sample and data analy-
ses were undertaken in London, with the exception of
the microarrays, which were processed at the Univer-
sity of California in Los Angeles. Informed consent
according to the Declaration of Helsinki (1991) and
ethical approval were obtained at each study site, with
all sites following an agreed standardized operating
procedure for subject assessment and sample collec-
tion. Subjects were nominally assigned to an AD, MCI,
or normal elderly control group as we have previ-
ously described [40, 42] and is summarized as follows.
Cases with probable AD were identified from primary
and secondary care services and diagnosed using the
NINCDS-ADRDA criteria [2] and Diagnostic and Sta-
tistical Manual of Mental Disorders (DSM-IV) [43].
MCI subjects were recruited from local memory clinics
and as such the MCI cohort was expected to be com-
posed largely of subjects with a likely AD-endpoint.
All MCI subjects reported problems with memory, cor-
roborated by an informant, but had normal activities
of daily living as specified in the Petersen’s criteria of
amnestic MCI [44, 45] and scored 0.5 on the Total Clin-
ical Dementia Rating Scale (CDR) or had a memory
score of 0.5 or 1 [46]. Within 2 years of the base-
line visit, some MCI subjects progressed to a clinical
diagnosis of AD (MCI-AD), while others remained
MCI (MCI-MCI). Normal elderly controls, defined
as having no evidence of cognitive impairment, were
recruited from primary care services and elsewhere.
Each subject underwent a semi-structured interview
to collect demographic and medical information. They
completed neuropsychological assessments including
the Mini Mental State Examination [47], Global Dete-
rioration Scale [48], and CDR [46]. Additionally, AD
patients were assessed by the Alzheimer’s Disease
Assessment Scale-Cognitive subscale [49], the care-
giver rated Neuropsychiatric Inventory scale [50], and
the caregiver rated Alzheimer’s Disease Cooperative
Study-Activities of Daily Living Inventory [51]. Con-
trol and MCI subjects were further assessed using the
CERAD battery [52]. Subjects were excluded from the
study if they were younger than 65 years, had signifi-
cant neurological or psychiatric illness other than AD,
significant systematic illness or organ failure, or a geri-
atric depression rating scale score ≥4/5 [53]. Subject
characteristics are summarized in Table 1.
Full blood cell count analysis
Approximately 3 ml of venous blood was collected
in K3EDTA vacutainer tubes (MidiMeds Limited).
Full blood cell count analysis was performed at the
Department of Haematological Medicine at King’s
College Hospital using an automated counter, accord-
ing to standard clinical practice. Samples within the
normal range ±10%, were available from 125 normal
elderly controls, 41 MCI subjects, and 73 AD sub-
jects. Extreme values outside the normal range for any
subject may represent an underlying episode of infec-
tion or peripheral inflammation and were therefore
excluded from further analysis. Following log10 trans-
formation of the data, linear regression was carried
out to assess the effect of disease status on individ-
ual leukocyte populations, adjusting for age, gender
and other blood cell types. All statistical analyses were
performed in SPSS or STATA.
Whole blood RNA extraction
Blood (∼2.5 ml) was collected in PAXgene blood
RNA vacutainer tubes (BD Diagnostics). The tube was
inverted 8–10 times following blood collection, stored
at −20◦C for 24 h and then −80◦C until RNA extrac-
tion. Where necessary, samples were shipped on dry ice
to London prior to RNA extraction. RNA was extracted
from all samples from their first visit and within two
years of collection as follows. After thawing PAXgene
tubes overnight at room temperature, total RNA was
extracted using the PAXgene blood RNA kit (Qiagen),
according to the manufacturer’s protocol. The quality
of the RNA was determined using the 2100 Bioanalyser
(Agilent Technologies). The average RNA integrity
number (RIN) across all samples was 8.8, standard
deviation 0.7. Only samples with a RIN >7.0 were used
in the analysis.
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Table 1
Subject characteristics of individuals used in Microarray and Blood cell count analyses
Microarray analysis Control MCI MCI-AD AD
Samples run on illumina BeadChips 116 83 44 113
Samples used in analysisa 105 78 42 104
Gender (M/F) 43/62 39/39 14/28 32/72
Age in years (±SD) 72.4 (6.4) 74.3 (5.6) 74.6 (6.8) 75.4 (6.7)
Disease duration in years (±SD) n/a n/a n/a 3.6 (2.1)
MMSE (±SD) 29 (1.2) 27 (1.7) 26 (2.3) 21 (4.6)
ADAS-cog (±SD) n/a n/a n/a 23 (10.0)
CDR sum of boxes (±SD) 0 (0.2) 1.3 (0.8) 2.1 (1.1) 6.5 (3.3)
Blood cell count analysis
Samples with available blood cell count data 125 41 n/a 73
Gender (M/F) 45/80 24/17 n/a 32/41
Age in years (±SD) 77.7 (6.3) 79.0 (4.6) n/a 80.3 (6.4)
Disease duration in years (±SD) n/a n/a n/a 4.3 (3.8)
MMSE (±SD) 29.0 (1.2) 27.8 (1.5) n/a 21.6 (5.4)
ADAS-Cog (±SD) n/a n/a n/a 19.3 (9.4)
CDR sum of boxes (±SD) 0.2 (0.3) 1.3 (0.7) n/a 6.3 (3.2)
aMicroarray data from 1 AD and 1 Control were excluded from further analyses because of a discrepancy between XIST expression gender
assignment and the original gender recorded for these participants; 20 samples were excluded due to an unacceptably low rate of detection on
the BeadChip; 2 MCIs were removed from further analyses because one subsequently converted to a diagnosis of Frontotemporal Dementia,
while the other case was subsequently diagnosed with a large meningioma. 1 AD was removed from further analyses due to a revoked diagnosis,
and 1 AD was removed due to a low RNA Integrity Number (RIN). Control subjects who converted to an MCI diagnosis (N = 4) and MCI
subjects who converted to an AD diagnosis within 2 years post-sampling (N = 42) were analysed as their status at sampling, unless indicated
in the text; MMSE, Mini Mental State Examination; CDR, Clinical Dementia Rating scale; Alzheimer’s Disease Assessment Scale-Cognitive
subscale (ADAS-Cog).
Microarray expression analysis and
pre-processing
A total of 356 (116 control, 127 MCI, and 113 AD)
RNA samples (Table 1) were processed on Illumina
Human HT-12 v3 Expression BeadChips (Illumina)
according to the protocol supplied by the manufacturer.
These chips contain 48,803 probes designed using
data from RefSeq (Build 36.2, Rel 22) and the Uni-
Gene (Build 199) databases. cDNA was synthesized
using 200 ng total RNA followed by amplification and
biotinylation of cRNA and hybridization according
to the protocol supplied with the Illumina Total-
Prep RNA Amplification Kit (Ambion). Following
hybridization, gene expression values were obtained
using the Lumi package within Bioconductor which
involves variance stabilization and quantile normaliza-
tion [54]. Outlier BeadChips with very low detection
rate (<80%), discrepancy in XIST gene expression and
recorded gender or serious co-morbid disease which
came to light on follow-up visits, were removed from
further analyses leaving 329 chips in the final anal-
ysis. Expression of XIST (ILMN 26235) is low or
absent in males, since the XIST gene is expressed
almost exclusively from the active X chromosome
present only in females. Probes that did not vary
across samples (largely representing non-expressed
genes in blood) were removed from subsequent
analyses, leaving 19,161 probes. Gene expression data
was adjusted for age, gender, RNA quality (RIN),
and study site and the residuals used for subse-
quent analyses. Gene expression differences between
diagnostic groups (control, MCI, and AD) were statis-
tically evaluated using linear models for microarray
analyses (Limma) [55]. P-values were adjusted for
multiple testing according to the false discovery
rate (FDR) procedure of Benjamini and Hochberg
and differentially expressed genes were selected
at FDR <0.01 [56] (supplementary Table 1; avail-
able online: http://www.j-alz.com/issues/30/vol30-3.
html#supplementarydata04). All statistical analyses
were performed in the statistical environment R using
Bioconductor packages.
Creation of weighted co-expression networks
We utilized the R package for weighted gene
co-expression networking analysis (WGCNA) [57], to
identify clusters (modules) of highly connected (cor-
related) genes. A full glossary of terms to describe the
analysis is available in supplementary data and at the
WGCNA web site (http://www.genetics.ucla.edu/labs/
horvath/CoexpressionNetwork/Rpackages/WGCNA/).
The underlying hypothesis is that such modules are
likely to possess a common function [58]. We
restricted the analysis to 9,970 of the 19,161 probes
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after (i) removing genes that were not expressed in
any sample, (ii) only using probes detected in at least
80% of samples in each diagnostic group, and (iii)
limiting to those annotated with Entrez Ids.
We estimated the connectivity of probes using
a pairwise Pearson correlation between all expres-
sions profiles resulting in an adjacency matrix. We
applied the topological overlap function to transform
this matrix into a topological overlap matrix (TOM)
adjacency (see glossary in supplementary data). This
replaces the original adjacencies with an intercon-
nected measure based on shared neighbors. To reduce
noise, we further filtered the probes to only include
those whose connectivity was above the median con-
nectivity on the TOM, leaving 4,985 probes for
subsequent analyses.
The modules were created dynamically by clus-
tering the TOM using the Ward linkage clustering
algorithm [59]. Each module is represented by an
arbitrary color assigned by the analysis software
according to size. We constructed signed networks,
which preserve the sign of correlations (i.e., direction
of expression change) among the expression profiles.
The connection strength between two genes was reg-
ulated by a soft threshold  =15, chosen by empirical
assessment of the network topology [57]. Introducing
a soft threshold allows generation of robust results by
maintaining gene co-expression information. Modules
were represented by a single expression profile, the
module eigengene (ME), which allowed us to explore
module behavior with respect to traits such as structural
changes in the brain. MEs represent the first principal
component for genes within each module. The MEs
were used to estimate the module membership (MM)
for each probe and thereby the extent to which a given
probe conforms to the characteristics of the module.
The correlation between individual gene expression
values and ME is used to calculate MM [58].
Module-trait correlations
To understand the significance of the modules
for disease, we correlated the MEs with discrete
phenotypic traits including: MCI throughout study
(MCI-MCI), MCI who were later diagnosed with
AD within a two year follow-up (MCI-AD), AD at
baseline (AD), and AD at baseline and/or follow-up
(ALL AD) and Disease Severity, which discretises
the severity of the disease using the following cod-
ing: control (0), MCI-MCI (1), MCI-AD (2), and AD
(3). The MEs were also correlated with structural mag-
netic resonance imaging traits (sMRI) including brain
volume and cortical thickness, previously shown to
be relevant in AD [42, 60–62] and available for the
same individuals: right entorhinal volume, left entorhi-
nal volume, total entorhinal volume, mean entorhinal
thickness, ventrical volume, left hippocampal volume,
right hipppocampal volume, total hippocampal vol-
ume, and whole-brain volume. A full description of
how the brain volume and cortical thickness measures
were generated for these subjects has been detailed pre-
viously [61, 62]. The module-sMRI trait correlations
were restricted to a subset of 239 subjects for which
a full set of trait information was available. A corre-
lation between each module and trait was considered
significant at p < 1 × 10−3 (Fig. 3).
The gene significance (GS) of a gene describes the
strength of the correlation between the probe and the
trait in question while the MM quantifies the extent to
which a gene conforms to the characteristics of a mod-
ule (i.e., it correlates with the ME). The combination
of MM and GS identifies genes which play important
roles in a given network module and are furthermore
significant for the clinical trait in question. The gene
significance and module memberships for the genes
with respect to the traits: MCI-MCI, MCI-AD, AD,
ALL AD, and Disease Severity are listed in supple-
mentary Tables 2–7. We plotted the MM against GS
for traits that correlated with MEs and highlighted
the genes that exhibit higher-than-median MM and
GS with respect to the trait. The pink, brown, and
turquoise modules were plotted against the MCI-MCI
trait because their MEs show significant correlation
with MCI-MCI in Fig. 3. For the same reason, the
black, blue and red modules were plotted against the
disease severity (DS) trait.
Gene enrichment analysis
We conducted enrichment analyses to describe the
functional characteristics of probes assigned to each
of the disease-associated modules. We tested for
enrichment of Gene Ontology (GO) terms associ-
ated with biological processes, molecular functions,
and cellular compartments. We also performed a
gene set enrichment analysis against KEGG Path-
ways using probes with both higher-than-median
MM and GS for each module, highlighted in green
in Fig. 5. The test was performed using DAVID
(http://david.abcc.ncifcrf.gov/), which calculates sig-
nificance of probe over-representation in particular
pathways [63]. We considered a pathway signifi-
cant at p < 5 × 10−4. We also investigated whether
groups of genes known to have direct disease-
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association or association with increased disease
risk, had higher-than-median MM and GS for any
module. The candidate gene list is presented in sup-
plementary Table 8 which includes the top 12 genes
associated with increased AD risk collated from Gene-
Wide Association Studies (GWAS) and available at
http://www.alzgene.org/ [64].
Module preservation between blood and brain
We first tested the blood modules for enrichment
using a large collection of brain-related gene sets
[65–86] where significance was computed using a
hypergeometric test. To further investigate the extent
by which disease associated changes present in periph-
eral blood reflect changes in AD brain we compared
our blood modules with two human AD brain expres-
sion datasets in more detail [77, 87]. To assess module
preservation, we used two statistical measures, the
Z-statistic and the median rank. The value of the Z-
statistic is directly proportional to how preserved the
blood module is in the brain data set: the higher the
value of a Z-statistic, the stronger the evidence that
the module displays significantly higher preservation
than expected by chance alone. Langfelder and col-
leagues suggests that a Z-statistic >10 indicates a
highly-preserved module, 2< Z-statistic <10 indicates
a somewhat preserved module while a Z-statistic <2
indicates very low confidence that the module is pre-
served [88]. Despite its usefulness, the Z-statistic tends
to give a better rank to modules of larger sizes. We
therefore also use the median rank, which is based on
the observed preservation statistics (as opposed to the
Z-statistics or p-value), and because it is less sensitive
to the size of the module, enabled us to compare the
relative preservation between modules. A module with
lower median rank suggests greater preservation than
a module with a higher median rank.
Preservation between blood and brain was explored
for both statistics with respect to two network prop-
erties: network density and network connectivity. To
ascertain preservation of network density, we exam-
ined the modules as a whole and determined whether
densely-connected modules in blood remained densely
connected in brain. To determine the preservation of
network connectivity, we examined the patterns of
connectivity at the probe level for each module in
blood and provided a score which determined whether
highly-connected probes central to the blood network
(also termed hub genes) remained highly-connected in
brain. Results are reported as Z-density, Z-connectivity
and Z-summary (the average of Z-density and
Z-connectivity) and median rank density, median rank
connectivity and median rank summary.
Blood cell types with over-represented changes in
gene expression
To characterize whether particular blood cell pop-
ulations were more affected in disease, probes with
significantly altered expression in AD (n = 2,270 with
FDR <0.01) were mapped on to a list of probes previ-
ously reported to be enriched in particular blood cell
types [89]. Over- or under-representation of signifi-
cantly altered genes was tested using the Pearson’s
chi-squared test, or the Fisher’s exact test if the num-
ber of probes was <10. To increase confidence in
our results, we also tested whether more cell lineage
probes attained a given p-value than would be expected
by chance. This was achieved by randomly selecting
2,908 of the 19,161 probes used in the analysis and
repeating the analysis for each cell-type specific list
for 10,000 permutations. We further tested for just
over-representation of significantly altered probes in
particular blood cells in AD blood using a hypergeo-
metric probability test.
RESULTS
Disease-associated gene expression differences
A large number of gene expression changes were
observed in blood from MCI and AD subjects com-
pared to normal elderly controls. Of the 2,908
differentially expressed probes identified between the
three groups (FDR corrected p < 0.01), around a quar-
ter were similarly altered in blood from MCI and AD
subjects, relative to controls (Fig. 1 and supplementary
Table 1). The probes which reached the greatest signif-
icance were predominantly down-regulated, although
overall, there were roughly equal numbers of sig-
nificantly up- and down-regulated probes below the
nominal p-value threshold.
Across blood samples, expression patterns could
be clustered together in to ten distinct modules, con-
taining between 171 (magenta) to 1,179 (turquoise)
probes (Fig. 2 and supplementary Tables 2–7). Mod-
ules are assigned an arbitrary color by the analysis
software according to their size. Six of these modules
had significant differences in mean ME expres-
sion between subject groups, with the red, black,
pink, brown, blue, and turquoise modules achiev-
ing p-values 3.7 × 10−9, 2.7 × 10−13, 3.7 × 10−5,
4.2 × 10−7, 2.6 × 10−5, and 8.6 × 10−9, respectively,
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Control-MCI
Control-AD MCI-AD
16,253
314
194 120
697
385 312
953
465 488
35
6 29
72
17 55
515
186 329
322
115 207
Fig. 1. Number of probes with differential expression between AD,
MCI, and control blood samples, FDR corrected p < 0.01. Direction
of change refers to an increase (↑) or decrease (↓) in expression of
control relative to MCI blood (Control-MCI), control relative to AD
(Control-AD), or MCI relative to control (MCI-AD), as indicated.
Fig. 2. Clustering dendrogram showing modules identified using
blood expression data from control, MCI, and AD subjects. Modules
are assigned an arbitrary color by the analysis software according to
their size: Red, Black, Yellow, Pink, Brown, Magenta, Green, Blue,
Purple, and Turquoise. The numbers of probes are indicated below
each module.
in Kruskal Wallis tests. Of these, the red, black,
pink, and brown modules were down-regulated in
MCI-MCI, and/or MCI-AD, AD, or Disease Sever-
ity, relative to controls (Figs. 3 and 4). As expected,
many of the structural MRI traits were positively
correlated with genes in these modules, whereby
reductions in brain volume and cortical thickness cor-
related with reduced gene expression (Fig. 3). Where
these modules differed from each other was in their rel-
ative levels of expression in AD subjects. Genes within
the black and red modules continued to display reduced
expression in blood from AD subjects, similar to that
seen in MCI subjects (e.g., ALL AD, r = −0.29, corre-
lation p-value p = 8×10−8, black module) (Figs. 3, 4a
and b), while expression in the brown and pink modules
abated in AD patients, achieving mean levels of expres-
sion more similar to control subjects (e.g., ALL AD,
r = −0.03, correlation p-value p = 0.6, brown module)
(Figs. 3, 4c and d).
The blue and turquoise modules displayed the oppo-
site pattern. They were upregulated in MCI-MCI,
MCI-AD, AD, and/or with Disease Severity relative
to controls (Figs. 3 and 4). Many of the sMRI traits
displayed negative correlation with these two mod-
ules (Fig. 3). The blue and turquoise modules differed
in their relative levels of expression in AD subjects.
Genes within the blue module continued to display
upregulated expression in blood from AD subjects,
similar to that seen in MCI subjects (ALL AD, r = 0.21,
correlation p-value p = 1×10−4) (Figs. 3 and 4e), while
expression in the turquoise module appeared to abate
in AD patients, achieving mean levels of expression
not significantly different from control subjects (All
AD, r = 0.056, correlation p-value p = 0.3) (Figs. 3
and 4f).
The turquoise, brown, and pink modules dis-
played changes in MCI subjects which appeared
to return toward normal levels in people clini-
cally diagnosed with AD (Figs. 3 and 4). We
therefore repeated the Kruskal Wallis tests after
excluding the control group to test for MCI-AD differ-
ences. There were significant differences in the pink
(p-value = 8.7 × 10−5), brown (p-value = 7 × 10−4),
and turquoise (p-value = 7 × 10−4) modules between
subjects with MCI and AD.
Functional identity of genes with altered
expression
The GO enrichment test [90] for each of the
disease-associated blood modules revealed important
associations for the red, black, pink, brown, blue,
and turquoise modules with particular GO terms, thus
providing a functional characteristic to each mod-
ule. For each module, GO terms with a p-value
<0.05 are summarized in Table 2. Overall, there were
strong associations in the red module with lower
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Fig. 3. Heatmap of module-trait correlations. The first four traits represent correlation of disease diagnosis (AD or MCI) relative to normal
elderly controls, within each module. MCI was further divided into subjects who subsequently converted to an AD diagnosis within 2 years of
sampling (MCI-AD) and those who did not (MCI-MCI). A further AD group (ALL AD) represents any subject who received a diagnosis of
AD during the two years of the study. Disease Severity (DS) was also analyzed. The remaining traits represent structural imaging measures of
regional brain volume or cortical thickness: right entorhinal volume (REV), left entorhinal volume (LEV), total entorhinal volume (TEV), mean
entorhinal thickness (MET), ventrical volume (VV), left hippocampal volume (LHV), right hipppocampal volume (RHV), total hippocampal
volume (THV) and whole-brain volume (WBV). For each module-trait pair the top-most value is the Pearson correlation coefficient while the
second (bracketed) value is the correlation p-value. The cell color represents the strength and direction of the correlation. Modules are assigned
an arbitrary color by the analysis software according to their size.
ribosomal function and translation, the black module
with decreased mitochondrial function and ribosomal
function and translation, the pink module with lower
secretory and endocytic function, the brown module
with decreased metabolic processes, the blue mod-
ule with altered immune function, and the turquoise
module with activation of transcription, in disease.
To further explore the genes that were most rep-
resentative of each module (module hubs) and were
also the most associated with disease-related traits,
we correlated module membership (MM) and gene
significance (GS), and selected probes which exhib-
ited higher-than-median MM and GS and determined
their enrichment in KEGG pathways (probes high-
lighted in green in Fig. 5). The scatter plots of GS
and MM (Fig. 5) show concordance with the results
presented in the heat map (Fig. 3): the more hub-like a
probe is, the greater its correlation with the trait in
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Fig. 4. Boxplots showing the mean module eigengene (ME) expression for the A). Ribosome/Translational, B) Ribosome/Mitochondrial, C)
Secretory/Endocytosis, D) Metabolic, E) Immune, and F) Transcription-related modules. MEs represent the first principal component of the
module gene members. Significance of differences in mean ME expression for each disease group determined by Kruskal Wallis tests. The
mean MEs were compared across diagnostic category: normal elderly control, AD and MCI. MCI was further divided into subjects who
subsequently converted to an AD diagnosis within 2 years of sampling (MCI-AD) and those who did not (MCI-MCI). The most significant
modules (p < 1 × 10−4) are represented in A to F.
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Table 2
GO enrichment test for each blood module revealing important associations between genes within each module
Module GO term names
Reda CCb ribosome, ribonucleoprotein complex, cytosolic ribosome, mitochondrion, cytosolic small ribosomal
subunit, cytosolic part, intracellular part, intracellular organelle, intracellular membrane-bounded organelle,
small ribosomal subunit
Ribosome/Translation BPc cellular metabolic process, translation, metabolic process, cellular biosynthetic process, cellular
macromolecule biosynthesis process, gene expression, macromolecule biosynthesis process, biosynthetic
process, positive regulation of helicase activity, response to redox state
MFd structural constituent of ribosome, non-membrane spanning protein tyrosine phosphatise activity,
oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor, NADPH:
quinine reductase activity, structural molecule activity, serine-type peptidase activity, serine hydrolase activity,
ATPase activity, peptidyl-prolyl cis-trans isomerase activity, transferase activity, transferring alkyl or aryl
(other than methyl) groups
Blacka CCb Ribosome, ribonucleoprotein complex, mitochondrion, mitochondrial part, mitochondrial inner membrane,
organelle inner membrane, mitochondrial membrane, mitochondrial envelope, intracellular organelle,
respiratory chain
Ribosome/Mitochondria BPc translation, oxidative phosphorylation, generation of precursor metabolites and energy, mitochondrial
electron transport, NADH to ubiquinone, ATP synthesis coupled electron transport, mitochondrial ATP
synthesis coupled electron transport, respiratory electron transport chain, cellular respiration,
ribonucleoprotein complex biogenesis, electron transport chain
MFd structural constituent of ribosome, structural molecule activity, hydrogen ion transmembrane transporter
activity, NADH dehydrogenase activity, NADH dehydrogenase (ubiquinone) activity, monovalent inorganic
cation transmembrane transporter activity, oxidoreductase activity, acting on NADH or NADPH, quinone or
similar compound as acceptor, oxidoreductase activity, acting on NADH or NADPH, RNA binding,
oxidoreductase activity
Pinka CCb secretory granule membrane, endomembrane system, clathrin-coated vesicle Golgi apparatus, endosome
membrane, synaptic vesicle
Secretory/Endocytosis BPc post-translational protein modification, protein amino acid phosphorylation, protein modification process,
activation of innate immune response, regulation of synaptic plasticity, regulation of long-term neuronal
synaptic plasticity, phosphate metabolic process, regulation of synaptic transmission, nuclear import,
regulation of neuronal synaptic plasticity
MFd GDP binding, GTPase activity, cAMP binding, co-SMAD binding, catalytic activity ligase activity, purine
nucleotide binding, phosphoprotein phosphatase activity, AMP binding, long-chain fatty acid-CoA ligase
activity
Browna CCb intracellular membrane-bounded organelle, membrane-bounded organelle, intracellular, intracellular part,
Golgi apparatus, centriole, endosome membrane, organelle membrane, recycling endosome, intracellular
organelle
Metabolic BPc amino sugar metabolic process, establishment of protein localization, steroid hormone receptor signaling
pathway, protein transport, glucosamine metabolic process
N-acetylglucosamine metabolic process, cellular aromatic compound metabolic process regulation of
anti-apoptosis, intracellular receptor mediated signaling pathway
MFd protein-L-isoaspartate (D-aspartate) O-methyltransferase activity, solute:hydrogen symporter activity,
nucleotide-sugar transmembrane transporter activity, O-methyltransferase activity,
beta-N-acetylhexosaminidase activity, polynucleotide adenylyltransferase activity, peptide hormone receptor
binding, sugar:hydrogen symporter activity, 7 S RNA binding, hydrolase activity, acting on carbon-nitrogen
(but not peptide) bonds, in linear amides
Bluea CCb plasma membrane, membrane, plasma membrane part, intrinsic to membrane, integral to plasma membrane,
intrinsic to plasma membrane, integral to membrane, membrane part, cell-substrate adherens junction
Immune BPc defense response, signal transduction, inflammatory response, response to wounding intracellular signaling
pathway, response to stimulus, immune response, immune system process, response to stress, cell surface
receptor linked signaling pathway
MFd signal transducer activity, receptor activity, transmembrane receptor activity, lipid binding, phospholipid
binding, cytokine receptor activity, phosphotransferase activity, alcohol group as acceptor, enzyme activator
activity, receptor signaling protein activity, cytokine binding
Turquoisea CCb nucleoplasm part, intracellular organelle part, nucleoplasm, nuclear lumen, nuclear part, protein complex,
intracellular membrane-bounded organelle, membrane-bounded organelle, intracellular organelle, MLL1
complex
Transcription BPc none
MFd protein binding, transcription coactivator activity, transcription activator activity, transcription regulator
activity, transcription cofactor activity, binding, transcription factor binding, molecular function,
methyltransferase activity, transferase activity
aTerms with a p-value <0.05 are summarized; bCC: Cellular Components; cBP: Biological Processes; dMF: Molecular Functions.
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question. In the turquoise (transcription) and blue
(immune) modules (Fig. 5E and F), probes highlighted
in green are in the top-right because these modules
showed a positive correlation with the trait, thus mak-
ing high gene significance a positive value. For all
other modules (Fig. 5A–D), high gene significance is
negative as the modules showed negative correlation
with the corresponding trait and therefore probes high-
lighted in green are in the bottom-right area instead.
The most significantly altered genes in MCI and
AD blood were in the black (ribosome/mitochondria)
module and compared to other modules, this module
(probes filtered for high MM and GS) also had the
most significant over-representation of genes enriched
in KEGG pathways including the AD pathway (supple-
mentary Tables 3 and 8 and supplementary Figure 1).
A striking number of probes in this module coded
for genes collectively associated with oxidative phos-
phorylation (OXPHOS), including subunits of the
respiratory chain and ribosomal subunits required
for translation of respiratory chain subunits (KEGG
pathways Oxidative Phosphorylation, p = 3.9 × 10−5;
Ribosome, p = 6.6 × 10−5; and Alzheimer’s disease,
p = 1.8 × 10−4, supplementary Figure 1 and supple-
mentary Table 10). Genes attributable to the KEGG
ribosome pathway were also enriched in the red (ribo-
some/translation) module (p = 1.7 × 10−7).
Following further analysis of the 77 genes assayed
which form part of the mitochondrial respiratory
chain (complex I to V) (OXPHOS), 32 were found
to be significantly dysregulated in MCI and/or AD
compared to control blood, with all but 3 genes show-
ing decreased expression in disease (supplementary
Table 8). Additionally, subunits of the mitochondrial
ribosome expressed from the nuclear genome (MRP
genes) and involved in translation of proteins for
the respiratory chain complex from the mitochondrial
genome, and/or ribosomal subunit genes involved in
nuclear gene translation, were down-regulated in dis-
ease. Of the 78 MRP genes assayed, 28 had lower
expression in MCI and/or AD compared to controls
(supplementary Table 8 and supplementary Figure 1).
GO analysis also revealed a significant over-
representation of immune-related genes in the blue
(immune) module with the most significant trait
and module-associated genes enriched in the Leuko-
cyte transendothelial migration KEGG pathway,
p = 1.2 × 10−4 (supplementary Tables 6 and 8 and
supplementary Figure 1). Immune related genes were
generally found in the blue (immune) and turquoise
(transcription) modules, displaying modest upregula-
tion of their expression in MCI and/or AD blood.
Most notable were genes which encode key adhesion
molecules within the selectin (L-, P-, and E-selectin,
P-selectin glycoprotein ligand 1), immunoglobulin
superfamily (ICAMs, VCAM, and madCAM), inte-
grin (CD11/CD18 and -4) and chemokine gene
families, which are crucial for leukocyte slowing,
rolling and tethering in response to activated endothe-
lial cell signals in blood microvessels (Fig. 5 and
supplementary Tables 1–8). Both subunits of the LFA-
1 (CD11a/CD18, ITGAL/ITGB2, L2) and Mac-1
(CD11b/CD18, ITGAM/ITGB2, M2) [91] com-
plexes were upregulated. There were also changes
in the genes encoding their downstream effectors
such as Fyn and FGR. The cell-cell and extracellular
matrix adhesion genes ITGAX and ITGB7 were upreg-
ulated whileCLDND1, a gene with adhesion properties
important for maintaining tight junction integrity and
regulating cell polarity was down-regulated. Mem-
bers of the ADAM family of type I transmembrane
glycoproteins, ADAM8, and ADAM10, were also
upregulated. These are known to be involved in cell
adhesion and processing of cytokines and adhesion
molecules [92]. In particular, ADAM8 has been shown
to cleave L-selectin from the plasma membrane of acti-
vated neutrophils, and through this activity is predicted
to facilitate transendothelial extravasation [93]. It is
also possible that upregulation of ADAM genes may
increase shedding of L-selectin to prevent rather than
increase cell adhesion and resolve inflammation, as has
been found for ADAM17 [94].
Other noteworthy genes altered in the blood of MCI
and/or AD people which might promote transendothe-
lial extravasation of leukocytes include progranulin
(GRN). The increase in expression of progranulin
in blood from people with MCI is consistent with
previous findings [95]. Progranulin can stimulate
neutrophil and macrophage infiltration and neovascu-
larization of wound tissue [96, 97] or alternatively
display anti-inflammatory activity as an antagonist
to TNF/TNFR signaling [98]. The expression of a
number of pattern recognition receptors important for
sensing a pathogenic or sterile stimulus [99], were
either upregulated as in the case of three NLR family
members (NLRP1, NLRP12, and NLRC5) and C-type
lectin domain receptors (CLEC16A) or down-regulated
(CLEC4D, CLEC4A, and CLEC7A and AIM2), in MCI
and/or AD subjects. Interestingly, TLR2 and TLR8,
which are part of the toll-like receptor family of pattern
recognition receptors, were not altered in MCI sub-
jects but were significantly upregulated in AD patients,
along with upregulation of FGR which mediates TLR
protein signals in addition to those of the LFA-1 and
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Mac-1 complexes. Some of these genes not only had a
strong disease association but also had expression pat-
terns characteristic of the modules in which they were
allocated (Fig. 5).
Of the candidate disease genes analyzed, only
SORL1 (blue-immune module) and BIN1 (turquoise-
transcription module) had higher-than-median module
membership and trait significance, suggesting they
may have significant influence over the behavior of
other genes in their respective modules (Fig. 5).
Other candidate genes including the disease associ-
ated genes NCSTN and GRN (turquoise-transcription
module) and GSK3B (blue-immune module) and
the AD susceptibility genes CR1 (blue-immune
module), ABCA7 (blue-immune module), PICALM
(pink-secretory/endocytosis module), and MS4A6A
(red-ribosome/translation module) while assigned to
modules either did not appear to be central to the
characteristics of the module and/or did not display
significant alteration in expression in disease.
Changes in blood cell number are unlikely to
explain the disease associated gene expression
differences observed in MCI and AD blood
Blood is a heterogeneous and dynamic tissue
containing many different leukocyte populations.
Leukocyte cell numbers can differ during disease and
inflammation. In light of this, we compared the num-
bers of circulating leukocytes in blood from AD, MCI,
and normal elderly control subjects to explore whether
the gene expression changes we observe might reflect
a shift in blood cell number or could potentially be
explained by the activity of a particular cell type in
blood. Of the three granulocyte populations investi-
gated, only the number of basophils, a minor cell type
in blood, was significantly different between control
and disease blood samples. There were more basophils
in blood from MCI and AD subjects compared to con-
trols (Fig. 6A; Bonferonni-corrected p < 0.017). The
numbers of neutrophils, eosinophils, and lymphocytes
(Fig. 6B–D) were similar between diagnostic groups,
while the numbers of monocytes, a particularly active
cell, were significantly lower in blood from MCI sub-
jects compared to AD (Fig. 6E; Bonferonni-corrected
p <0.017). All subjects included in the analysis had
blood cell numbers considered to be within the nor-
mal acceptable range for each cell type, indicating the
changes we observed were small and not indicative of
serious illness.
None of the leukocyte populations investigated had
greater numbers of differentially regulated genes than
any other cell type, given the total number of dysregu-
lated between control, MCI and AD and the numbers of
genes analyzed (supplementary Table 9). There were
in fact fewer dysregulated genes representing activated
granulocytes in MCI and B cells in AD than might
be expected, suggesting activity in these cells was
unlikely to explain a significant proportion of the gene
expression differences we observed in disease (sup-
plementary Table 9). Overall, our data suggests no one
cell type is likely to be driving the gene expression
changes we observe in disease and that the disease-
related changes we report are not a simple reflection
of a shift in cell numbers in disease.
Blood and brain module preservation
There was significant concordance between blood
modules and brain-related modules generated from
multiple published expression and protein datasets
generated from brain tissue (supplementary Table 10).
For example, the black (ribosome/mitochondria) mod-
ule was significantly enriched with genes from brain
modules, displaying a similar direction of change of
expression in disease and preservation of module char-
acteristics across datasets and species (supplementary
Table 10). To explore this further, we investigated
two well-powered studies of gene expression gen-
erated from hippocampus [77] and cortical regions
[87] from control and AD patients. The black (ribo-
some/mitochondria) module showed high density
preservation but was less preserved with respect to
connectivity (Fig. 7), indicating a possible change in
roles for the hub genes in the brain, although it should
be noted that the two brain datasets alone did not
Fig. 5. The correlation between module membership (MM) and gene significance (GS) for each probe was computed. Scatterplots for the most
significant traits and modules are presented, illustrating the relationship between MM and GS at the probe level and indicating how central a
given probe is to each module and how associated it is with the traits we examined of disease severity (A, B, and E) or MCI relative to control
(MCI-MCI) (C, D, and F). The following six modules were used for correlation: Red (ribosome/translation) (A), Black (ribosome/mitochondria)
(B), Pink (secretory/endocytosis) (C), Brown (metabolic) (D), Blue (immune) (E), and Turquoise (transcription) (F). Probes highlighted in green
exhibited higher-than-median module membership and trait significance, so are likely to be core module probes. Probes encoding mitochondrial
protein subunits of complex I to V of the respiratory chain and protein subunits of the mitochondrial ribosome (listed in supplementary Table
8) are colored in purple, while probes encoding important immune-associated genes (listed in supplementary Table 8) are colored in dark pink.
Candidate genes, which are listed in supplementary Table 8, are highlighted by gene name.
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Fig. 6. A Full Blood Count analysis was undertaken to compare the numbers of various leukocyte populations in blood from AD, MCI, and
normal elderly subjects. Three granulocyte populations were examined: basophils (A), neutrophils (B), and eosinophils (C) and two peripheral
blood mononuclear populations, lymphocytes (D) and monocytes (E). Data within the normal range (±10%) was included in the analysis. Graphs
represent mean leukocyte number (×109/liter) ± SEM in normal elderly controls (n = 125), MCI (n = 41), and AD subjects (n = 73). Following
log10 transformation of the data, linear regression was carried out to assess the effect of disease status on individual leukocyte populations,
adjusting for age, gender, and other blood cell types. *Significance, Bonferonni-corrected p < 0.017.
show particularly high connectivity concordance with
each other (data not shown). In the hippocampus, the
black (ribosome/mitochondria) module had Z-density
and Z-summary >10 (threshold for high preserva-
tion) which was the highest among all the modules
and had the highest median rank density statistics.
In cortical tissue, the black (ribosome/mitochondria)
module maintained Z-density >10 and ranked sec-
ond highest with respect to median rank and median
rank density. This pattern did not appear in the
Z-connectivity and median rank connectivity statis-
tics. Another module which showed some preservation
across both data sets was the brown (metabolic) mod-
ule. Again, the preservation patterns were stronger
in the hippocampus than in cortical tissue. Connec-
tivity of the brown (metabolic) module was more
preserved than the black (ribosome/mitochondria)
module. The red (ribosome/translation) module was
only preserved in the hippocampal brain data, while
the pink (secretory/endocytosis) module, which was
associated with changes in MCI subjects only, showed
only weak preservation in both brain datasets. Finally,
the turquoise (transcription) and blue (immune) mod-
ules appeared to be unpreserved in the hippocampus,
but at least for the turquoise (transcription) module,
more highly preserved in cortical tissue than in the
hippocampus.
DISCUSSION
We have identified a large number of differentially
expressed genes in blood samples from MCI and AD
subjects compared to normal controls using microarray
technology. These dynamic changes could be grouped
in to six disease-associated co-expression modules
each containing genes with characteristic biological
identities. There were strong associations in the red
module with lower ribosomal function and translation,
the black module with decreased mitochondrial
function and translation, the pink module with lower
secretory and endocytic function, the brown module
with decreased metabolic processes, the blue module
with altered immune function and the turquoise
module with promotion of transcription in disease.
Disease was most strongly associated with lower
expression of genes encoding respiratory chain sub-
units or ribosomal protein subunits which translate
respiratory subunit genes from the mitochondrial
genome. These genes were predominantly allocated to
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Fig. 7. The blood module preservation results across the two publically available AD human brain gene expression data sets (Liang (A) and
(B) Myers [77, 87]). The scatter plots describe the relation between the different modules and the six module-preservation statistics. For each
plot, the x-axis corresponds to the module size while the y-axis is the value of the preservation statistics in question. Each plot contains the ten
modules represented by their colors. The dotted lines represent the nominal strength of the relationship: the higher the value of a Z-statistic, the
stronger the evidence that the module displays significantly higher preservation than expected by chance for Z-summary, Z-density, and median
rank intensity.
the black (ribosome/mitochondria) module and were
present in both AD patients and MCI subjects, includ-
ing those known to have prodromal AD (MCI-AD).
The production of ATP and respiratory chain activity
therefore appears to be compromised early in disease.
Mitochondrial (respiratory chain) dysfunction is a
consistent hallmark of AD
Platelets and lymphocytes have previously been
found to have significantly reduced respiratory chain
activity in MCI and AD subjects [16, 22–24]. In
agreement with our findings, several studies have
shown decreased cytochrome c activity (complex IV)
in human platelets from AD patients [22, 100, 101]
and lower abundance of complex IV proteins in blood
from people with MCI [24]. Remarkably, the changes
we observe in the respiratory chain in AD blood are
also well-preserved in brain in terms of density of
the black module, particularly in the hippocampus
[15, 77, 102], suggesting a shared disease response
between these two tissues. Down-regulation of res-
piratory chain subunits and genes that regulate their
transport in to the mitochondrion have been previ-
ously described in AD in a number of brain regions
at both the RNA and protein levels [103]. Alterations
to the OXPHOS/respiratory chain may in part provide
an explanation for the significantly reduced glucose
metabolism measured by FDG-PET which manifests
very early in disease [104]. The overlap between blood
and brain may represent a common response to the
same disease-associated signal(s). A direct and indirect
link between toxic A species and respiratory chain
activity has been well described in AD brain tissue
[105], and it is plausible that the changes in circulat-
ing levels of A in plasma [106] or the increase in A
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Fig. 7. (continued)
associated with blood vessels could provide the signal
to blood cells in the periphery, resulting in the same
genes being affected. Other more indirect signals may
also be responsible.
Inherited mutations in respiratory chain subunits
and assembly genes which we find down-regulated in
the current study, including NDUSF4 [107], NSUSF3
[108], NDUFA1 [109, 110], UQCRB [111], UQCRQ
[112], and MRPS22 [113, 114], can cause loss of activ-
ity in complexes I, II, III, IV, and/or V and give rise
to complex disease phenotypes which include Leigh
syndrome, Leigh-like syndrome, fatal infantile lactic
acidosis, neonatal cardiomyopathy with lactic acido-
sis, macrocephaly with progressive leukodystrophy,
and unspecific encephalomyopathy [115]. Of partic-
ular relevance to the current study is the frequent
occurrence of neurodegeneration in such diseases. The
respiratory chain operates as a supercomplex involving
complex interactions involving around 100 proteins
derived from the nuclear and mitochondrial genomes,
assembled in to five complexes. Each complex involves
variable assemblies of components to enable precise
and dynamic control of thermodynamic and kinetic
properties and thereby the modulation of functions
including ATP generation [116]. It is difficult to pre-
dict with accuracy how a change in abundance of an
individual protein subunit would affect the respira-
tory chain beyond the individual complex in which the
affected subunit is located.
Nevertheless, compromised respiratory chain activ-
ity is expected to affect ATP production and increase
cellular stress and generate excessive production of
mitochondrial reactive oxygen species (mROS) which
can damages cell components and lead to cell death.
Mitochondria generate a significant amount of ROS
when the respiratory chain, particularly complexes I
and III, are compromised [117, 118]. mROS is believed
to be one of the main events contributing to neuronal
cell loss in AD and other related neurodegenerative
disorders [119, 120]. Consistent with our findings,
freshly isolated platelets [22] and lymphocytes [121,
122] from AD patients have decreased ATP levels,
increased levels of ROS, and increased expression of
genes associated with oxidative stress [18, 21], and
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there is evidence of oxidative damage to plasma pro-
teins, occurring even in mild disease [123]. Leukocytes
are also more susceptible to respiratory chain inhibitors
[121, 124–126] and have elevated DNA fragmenta-
tion and spontaneous apoptotic cell death [127–130].
Apoptosis of leukocytes in tissues is normally a crit-
ical mechanism for rapidly resolving inflammation
and avoiding collateral inflammatory tissue damage by
activated cells [131, 132]. We did not observe changes
in genes encoding apoptotic markers in our samples,
although activation of many of these genes is more
likely to occur post-translationally and therefore would
not be observed in our study. It will be important to
establish if the changes we see lead to increased blood
cell apoptosis in patients with MCI or AD and their
increased clearance from circulation.
While excessive ROS can be detrimental, mROS is
also an important intermediate signal for normal cell
function. In the immune system, it can mediate signal-
ing pathways including the RLR-dependent antiviral
responses [133] and the TLR-dependent response
[134], both of which signal through the NF–B, MAPK
[135], ERR–PGC1 [136], and/or NLRP3 inflamma-
some [137] pathways to generate an immune response.
mROS can enhance pro-inflammatory cytokine pro-
duction and stimulate the oxidative burst in activated
cells. The increase in activation markers we observe
could therefore herald a healthy innate immune
response characterized by increased leukocyte adhe-
sion to the endothelium [138] and mobilization of
these cells to the site of tissue injury. It will be
important to establish whether the changes we find in
mitochondrial genes are sufficient to increase mROS
and support a healthy pro-inflammatory environment
or alternatively, lead to excessive mROS production
and a reduction in chemotactic behavior, oxidative
burst, reduction in glycolysis, and cell clearance
through apoptosis to prevent further immune activity
[139, 140].
Immune activation is a prominent feature of AD
Our data support the presence of a chronic low grade
innate immune response in people with MCI and AD.
Important signaling, cell adhesion, and motility gene
markers were upregulated, consistent with leukocytes
having an activated phenotype, which is expected to
increase endothelial cell association, leukocyte rolling,
and transendothelial extravasation (diapedesis). These
genes are predicted to be blood specific, so it is no sur-
prise that the blue (immune) module which they mainly
belong to was not highly conserved in the brain. Acti-
vation of these genes is predicted to have arisen from a
sterile immune response initiated in the brain [141]
with the changes we observe likely to be part of a
sustained and chronic peripheral response. Increased
brain-associated inflammatory activity and systemic
changes have been extensively described in AD. A
and/or dying neuronal cells are thought to trigger a
local sterile immune response in AD brain [99, 142].
A can bind to a multitude of receptors expressed on
brain microglia, and can elicit the production of pro-
and/or anti-inflammatory mediators such as cytokines
and chemokines and ROS, which may exacerbate dis-
ease [143–147]. Alongside this cascade of events,
alterations in the levels of acute phase proteins, in par-
ticular chemokines, pro-inflammatory cytokines [35,
148, 149], endothelial markers [150], and markers of
complement activation [33, 151–153] have all consis-
tently been found in blood early in AD and are thought
to coincide with endothelial signals which in turn
increase leukocyte migration into the brain, perhaps
further propagating the inflammatory response [144,
154–157]. Polymorphisms in genes with inflammatory
functions have emerged as important pathways which
confer disease susceptibility in many GWAS studies
[158–164]. Interestingly, variants of the sortilin-related
receptor (SORL1) gene (a central hub in the blue-
immune module), which was significantly upregulated
in the blood of people with MCI, is a susceptibility
gene for AD, albeit the increased risk is very small
[165]. SORL1 has been shown to functionally interact
with APP, preventing homodimer formation which is
believed in turn to affect secretase activity and APP
processing, culminating in decreased production of
amyloidogenic products [166]. A peptides are abun-
dant in human plasma and have been evaluated as
possible biomarkers for AD. A net increase in SORL1
expression, which we found in MCI blood, may in part
be responsible for the decrease in A peptides found
in plasma from prodromal AD patients [167]. Further-
more, SORL1 expression was lower in AD subjects
compared to MCI blood, which coincides with the pres-
ence of higher A peptides in people with AD [168].
As SORL1 is a multifunctional protein thought to be
important in the endocytic pathway, it may have addi-
tional roles in disease which could include controlling
some of the immune-associated genes co-expressed
in the blue (immune) module. It will be particularly
interesting to test whether the AD-associated SORL1
variants previously identified are able to exert a trans-
acting influence over the expression of any other genes
in the blue (immune) module.
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Despite the presence of immune activation signals
and markers of response, it is unclear whether the
changes we see in disease represent diapedesis of
leukocytes across the blood brain barrier. The degree
of differential expression between control and dis-
ease blood was less significant for immune-related
genes than for other differentially expressed genes.
As the cells we sample in venous blood are still
circulating they are not expected to have displayed
sufficiently strong activation signals to enable them
to have crossed the blood brain barrier (BBB). No
study has yet reported an increase in the expression
of the most important endothelial-specific adhesion
molecules (ICAM-1, VCAM-1, and E selectin) at the
BBB capillaries in AD, which would be necessary to
bind the adhesion proteins we find increased in leuko-
cytes at the RNA level [169]. There are, however,
reports of clear disruption of the BBB and changes
consistent with activation of endothelial cells and
increased permeability, particularly in advanced dis-
ease [170–175], which is consistent with the profile we
found. In some studies, significant numbers of mono-
cytes [144, 154, 176–178] and T-lymphocytes [157,
179–182] are detectable in AD brain. However, as the
mice used in these studies were grafted with GFP-
expressing hematopoietic cells following irradiation,
cell infiltration into the brain could be attributable to
loss of BBB integrity as a consequence of irradia-
tion [157, 183]. Other studies find very little evidence
for significant leukocyte infiltration in the brain in the
absence of disease [184]. It will be important to estab-
lish whether the activated phenotype we observed in
blood cells very early in disease ultimately results in
these cells being able to cross the BBB in patients,
or merely reflects a priming of this process. Even if
these cells do not actually cross the BBB, the markers
of chronic activation we observed suggest these cells
could be contributing to the pathology observed at the
BBB in AD perhaps by producing damaging ROS.
Genes assigned to the pink, brown, and turquoise
modules (associated with secretory/endocytic path-
ways, metabolism, and transcription, respectively)
were altered in MCI blood, but generally returned
to normal levels in AD patients. These changes may
reflect protective or compensatory mechanisms acti-
vated when disease first emerges which abate when
established clinical symptoms of disease develop.
Interestingly, the two AD susceptibility genesPICALM
and BIN1 [158, 159, 162–164, 185], both believed to
be important proteins involved in endocytic processing
[186, 187], displayed this type of expression pattern.
BIN1 was central to the characteristics of the turquoise
(transcription) module displaying significantly greater
expression in MCI subjects and lower expression in
AD patients. BIN1 may be an important regulator of
expression of other transcription-associated genes in
the turquoise (transcription) module, which would be
consistent with a role previously described for this gene
[188].
Changes are likely to be cell autonomous
None of the individual leukocyte cell populations
analyzed had a higher proportion of cell marker genes
altered in MCI or AD than any other cell type, despite
MCI patients having significantly fewer monocytes
than control and AD patients, and MCI and AD patients
having higher numbers of basophils. This indicates
no preferential activation of any one particular cell
type in disease and suggests that our results do not
merely reflect a change in the proportion of different
cells in blood. Compared to other cells, B lymphocytes
had relatively fewer gene expression changes in AD
than might be expected by chance, suggesting that this
branch of the adaptive immune system may not be acti-
vated in AD [99]. Similar changes in blood cell number
have been reported previously [189]. Importantly, our
findings suggest that the differentially expressed genes
largely represent disease-associated cell autonomous
changes and do not merely reflect changes in cell num-
bers, as there was no clear association between gene
expression and individual blood cell populations.
The promise of blood for screening
The strong concordance between the respiratory
changes in AD blood and brain suggests blood might be
a good model for testing novel therapies, particularly
those that target mitochondrial dysfunction. Neuropro-
tective strategies to neutralize oxygen radicals or alter
respiratory chain activity to prevent oxidative damage
in AD have been strongly pursued with many drugs
such as Coenzyme Q derivatives and Dimebon now
being tested in clinical trials. While clearly a rele-
vant target in AD, results of clinical trials targeting
mitochondrial dysfunction have thus far been very
disappointing. A greater effort to screen promising can-
didates for disease efficacy in ex vivo blood cultures, or
using the markers we have identified as outcome mea-
sures in in vivo screening studies, may perhaps improve
the identification of promising candidates and provide
data to help triage drugs to progress into clinical trials.
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CONCLUSIONS
Overall, it is possible the weak inflammatory signal
we find could be offset by the much stronger changes
in respiratory chain activity which may be expected to
lead to blood cell clearance from circulation to prevent
collateral tissue damage. Our results are particularly
exciting as they demonstrate mitochondrial and inflam-
matory changes in the periphery occur very early in
AD, some of which are also known mechanisms occur-
ring in AD brain. Fundamentally, these could be used
as the basis for identifying people early in disease
and for monitoring the efficacy of novel therapeutics
for a range of disorders characterized by mitochon-
drial dysfunction in the CNS and blood. Resolving
inflammation and preventing oxidative damage are
very active areas being explored as possible targets
for drug development in AD and our findings suggest
blood could be a very good model in which to evaluate
their efficacy.
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